• Home
  • PATH-53. DNA MUTATION SEQUENCING AND METHYLATION ANALYSIS OF SOMATICNF1 MUTANT IDH-WILDTYPE GLIOBLASTOMA IDENTIFIES THREE EPIGENETIC GROUPS ANDCDKN2A/B LOSS AS A NEGATIVE PROGNOSTIC BIOMARKER.

PATH-53. DNA MUTATION SEQUENCING AND METHYLATION ANALYSIS OF SOMATICNF1 MUTANT IDH-WILDTYPE GLIOBLASTOMA IDENTIFIES THREE EPIGENETIC GROUPS ANDCDKN2A/B LOSS AS A NEGATIVE PROGNOSTIC BIOMARKER.

Author List
Kanish Mirchia, Sixuan Pan, Emily Payne, John Liu, Zain Peeran, Poojan Shukla, Jacob Young, Rohit Gupta, Jasper Wu, Joanna Pak, Kyounghee Seo, Tomoko Ozawa, Brian Na, Alyssa Reddy, Steve Braunstein, Joanna Phillips, Susan Chang, David Solomon, Arie Perry, David Raleigh, Mitchel Berger, Adam Abate, Harish Vasudevan
Publication
Neuro-oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/564361713
Publication Year
2024
Publication Title
Kanish Mirchia, Sixuan Pan, Emily Payne, John Liu, Zain Peeran, Poojan Shukla, Jacob Young, Rohit Gupta, Jasper Wu, Joanna Pak, Kyounghee Seo, Tomoko Ozawa, Brian Na, Alyssa Reddy, Steve Braunstein, Joanna Phillips, Susan Chang, David Solomon, Arie Perry, David Raleigh, Mitchel Berger, Adam Abate, Harish Vasudevan. PATH-53. DNA MUTATION SEQUENCING AND METHYLATION ANALYSIS OF SOMATICNF1 MUTANT IDH-WILDTYPE GLIOBLASTOMA IDENTIFIES THREE EPIGENETIC GROUPS ANDCDKN2A/B LOSS AS A NEGATIVE PROGNOSTIC BIOMARKER. Neuro-Oncology. 2024 Nov 11; 26(Supplement_8):viii191-viii191.